Cannabidiol for self-injury in children with severe developmental disorders
Treatments studied
Part of Mental health clinical trials.
This study tests whether cannabidiol (a substance from cannabis that doesn't cause a high) can reduce severe self-injurious behaviors in children and teens with severe developmental disabilities whose symptoms haven't improved with other medications. The goal is to help reduce harm and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child or teen between 5 and 17 years old, weighing 12–49.9 kg (roughly 26–110 pounds)
- Diagnosis of severe developmental disability requiring help with daily activities like eating, dressing, and toileting
- Severe self-injurious behavior occurring multiple times daily in the past week, despite treatment
- Already tried strong psychiatric medications (like risperidone or aripiprazole) for at least 30 days without improvement
- No changes to medications or therapy in the past month
- A trusted caregiver able to attend all visits and help track progress
- Both parents or guardians must sign permission; no current use of cannabis or cannabidiol in past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether cannabidiol (CBD) given during an inpatient alcohol detox helps people stay off alcohol afterward. You would be compared with standard care to see if CBD improves recovery during and after withdrawal.
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
This study tests whether deep brain stimulation can reduce severe self-injurious behaviors in children with autism. If standard treatments haven't worked, this approach may offer a new option.
This Phase 2 study tests CBDV, a form of cannabis-based medicine, compared with placebo (dummy medicine) in children with autism who have significant irritability and social challenges. It aims to see whether CBDV can improve behavior and overall symptom severity safely over the study period.
This study tests whether cannabidiol (CBD) can help young adults who use cannabis heavily but aren't looking to quit. You'll take a CBD pill and see if it changes your cannabis use or related symptoms.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Hear when a new Neurodevelopmental Disorders With Severe Self-injuries trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.